Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Last Day:
Midcap Stocks with
Strong Growth Potential

Get Our Research at 70% Off


See the Stocks

**Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
**By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

LYKA LABS Share Price   (LYLB)



Here is the latest stock price and chart of LYKA LABS. For more details, see the LYKA LABS company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.

REFRESH
Live BSE Quotes May 14, 2026 12:59:00 PM
Price (Rs)62.40 Open (Rs) 59.55 High (Rs) 62.40 Low (Rs) 59.11
% Change0.73 Volume 224 Value (Rs) 13,978 52-Week H/L 128.60 / 44.49
Live NSE Quotes May 14, 2026 12:59:15 PM
Price (Rs)63.25 Open (Rs) 61.89 High (Rs) 63.25 Low (Rs) 59.20
% Change1.62 Volume 14,414 Value (Rs) 880,407 52-Week H/L 128.78 / 44.10
Change
1 Day
0.73%		1 Month
10.34%		3 Months
-8.24%		1 Year
-43.73%		5 Years (CAGR)*
5.70%		10 Years (CAGR)*
-1.56%

* Compound Annual Growth Rate

Valuation
EPS (Rs)* -0.10 P/E Ratio (x) NM Market Cap (Rs m) 2,227.06 P/BV (x) 2.19 Dividend Yield (%) 0.00
  *Trailing 12 months earnings, excluding extraordinary / exceptional items. BSE Sensex | CNX Nifty

Charts
Loading...
  
Peer Group:
Quote & Graph
     
 S&P BSE SENSEX 
PERIOD
Advanced Charts new
Charts by TradingView

LYKA LABS Share Price Today:

LYKA LABS last traded price was up 0.7% to Rs 62.4 on the BSE. On the NSE, LYKA LABS last traded price was up 1.6% to Rs 63.3. The total volume of shares traded was 0.0 m.

Overall, the broader S&P BSE HEALTHCARE Index was up by 1.9%. And the benchmark S&P BSE SENSEX was at 75,422.2 (up 1.1%).

Over the last 30 days, the LYKA LABS share price is up 9.0%. And over the last one year, LYKA LABS share price is down 43.1%.

The current market capitalisation of LYKA LABS stands at Rs 2,227.06 m. For more information, check out the list of top 100 companies in India in terms of market cap.

As of March 2026, company promoters held 58.16% stake in LYKA LABS, with no shares having been pledged. To know more, check out the latest shareholding pattern of LYKA LABS.

Before you go, here's an alert on LYKA LABS you may want to take note of...

Upcoming Corporate Actions for LYKA LABS

DateAnnouncementEx-Date
25-May-2026Quarterly Results-
Data Source: Equitymaster, Accord Fintech

List of All Upcoming Corporate Actions



FAQs on LYKA LABS

What is the LYKA LABS share price today?

The last traded price of LYKA LABS was Rs 62.4 on the BSE, up 0.7% over the previous close. On the NSE, LYKA LABS last traded price was up 1.6% at Rs 63.3.

What is the market cap of LYKA LABS?

The current market capitalisation of LYKA LABS stands at Rs 2,227 m. For more information, check out the list of top 100 companies in India in terms of market cap.

What is the Earnings per share (EPS) of LYKA LABS?

LYKA LABS had an EPS of Rs -0.1 in the latest financial year. In the most recent quarter, the company declared an EPS of Rs -0.0.

What is the Dividend Yield of LYKA LABS?

For the financial year 2025, LYKA LABS declared dividend amounting to Rs 0.0 per share. At the current price of Rs 62.4, this results in a dividend yield of 0.0%.

Which are the top pharmaceuticals companies in India by marketcap?

Based on marketcap, these are the top pharmaceuticals companies in India:

You can see the full list of pharmaceuticals stocks ranked by marketcap here.

Also, here's one of our more popular screens related to marketcap: India's Biggest Companies by Marketcap.

Which are the biggest pharmaceuticals companies in India by sales?

Based on sales, these are the top pharmaceuticals companies in India:

You can see the full list of pharmaceuticals stocks.

Curious to know which Indian companies are growing their sales at a faster rate than their peers? Check out India's Fastest Growing Companies by Sales.

Which are the biggest pharmaceuticals companies in India by net profit?

Based on net profit, these are the top pharmaceuticals companies in India:

You can see the full list of pharmaceuticals stocks.

In case you are wondering which company logs in the biggest net profit margin in India, check this out: High Profit Margin Companies in India.


Today's Market

Sensex Today Trades Higher | Nifty Above 23,450 | Bharti Airtel & Tata Steel Top Gainers Sensex Today Trades Higher | Nifty Above 23,450 | Bharti Airtel & Tata Steel Top Gainers(10:30 am)

Asian markets traded mixed on Thursday ahead of the meeting between US President Donald Trump and his Chinese counterpart Xi Jinping for clues on the future of US-China ties.

ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Quantum Information Services Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

  • Registered Name:

    Quantum Information Services Private Limited

  • Registered Office Address:

    103, Regent Chambers, Nariman Point, Mumbai 400021

  • CIN:

    U65990MH1989PTC054667

  • Website:

    www.equitymaster.com

  • Compliance Officer & Grievance Officer:

    Ms. Sonal Ramachandran

    | Telephone No.: +91-22-61434003 | Email: compliance@equitymaster.com

SEBI Registered Research Analyst Details:

SEBI Registration No.: INH000021128 | Type of Registration: Non-Individual | Validity: Perpetual | BSE Enlistment No: 6769

Principal Officer: Tanushree Banerjee | Telephone No.:+91-22-61434055 | Email: po.ra@equitymaster.com

SEBI Registered Investment Adviser Details:

SEBI Registration No.: INA000000680 | Type of Registration: Non-Individual | Validity: Perpetual | BSE Enlistment No: 1488

Principal Officer: Vivek Chaurasia | Telephone No.:+91-22-61434055 | Email: po.ria@equitymaster.com

SEBI Office Details:

SEBI Bhavan BKC
Address: Plot No.C4-A, 'G' Block Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra
Telephone No.: +91-22-26449000 / 40459000 | Fax: +91-22-26449019-22 / 40459019-22 | Email: sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575
SCORES: https://www.scores.gov.in/ | SMARTODR: https://smartodr.in/login

Association of Mutual Funds of India (AMFI) Registered Details:

AMFI Registered Mutual Fund Distributor
AMFI Registration Number : ARN - 1022
Date of Initial Registration : 28 / JAN / 2008
Current Validity of ARN upto : 28 / JAN / 2028

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, enlistment with BSE as IA and RA, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing any content from this website whether wholly or in part, for any purpose without the permission of Quantum Information Services Private Limited is strictly prohibited and shall be deemed to be copyright infringement.

Quantum Information Services Private Limited (QIS) is a SEBI registered Research Analyst (bearing registration no INH000021128) and Investment Adviser(Reg. No: INA000000680). Consequent upon the merger of Equitymaster Research Private Limited into QIS, effective October 30, 2025 QIS owns and operates brand 'Equitymaster' and website www.equitymaster.com. This does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities and QIS including its employees, personnel, directors, associates will not be liable for any losses (direct or indirect) incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. All content and information is provided on an 'As Is' basis by QIS. Information herein is believed to be reliable but QIS does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. The services rendered by QIS are on a best effort basis. QIS does not assure or guarantee the user any minimum or fixed returns. The securities quoted, if any are for illustration only and are not recommendatory. Use of this information is at the user's own risk. The user must make his own investment decisions based on his specific investment objective and financial position and using such independent advisors as he believes necessary. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject QIS or its affiliates to any registration or licensing requirement.

The performance data quoted represents past performance and does not guarantee future results. As a condition to accessing QIS's content and website, you agree to our Terms and Conditions of Use, available here.